Literature DB >> 28750807

Approaches to Assess Biased Signaling at the CB1R Receptor.

Robert B Laprairie1, Edward L Stahl1, Laura M Bohn2.   

Abstract

G protein-coupled receptors, such as the cannabinoid type 1 receptor (CB1R), have been shown to interact with multiple binding partners to transmit signals. In both transfected cell systems and in endogenously expressing cell lines, CB1R signaling has been described as multifaceted. The question remains as to how this highly widely expressed receptor signals in a given cell at a given time in vivo. The concept of functional selectivity, or biased agonism, describes the ability of an agonist to engage the receptor in a manner that preferentially engages certain signaling interactions (e.g., G proteins) over others (e.g., β-arrestins), presumably by stabilizing certain receptor conformations. There is growing interest in using such properties of ligands to direct signaling downstream of CB1R toward desirable therapeutic outcomes and to avoid adverse side effects. While it is not currently clear what pathways should be engaged and which should be avoided, the development of biased agonist tool compounds will aid in answering these questions. In this chapter, we discuss the approaches and caveats to assessing biased agonism at the CB1R.
© 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biased signaling; CB1; Cannabinoid

Mesh:

Substances:

Year:  2017        PMID: 28750807      PMCID: PMC6953168          DOI: 10.1016/bs.mie.2017.06.031

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  60 in total

1.  The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins.

Authors:  Jane E Lauckner; Bertil Hille; Ken Mackie
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

Review 2.  Ligand- and heterodimer-directed signaling of the CB(1) cannabinoid receptor.

Authors:  Brian D Hudson; Terence E Hébert; Melanie E M Kelly
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

3.  An overview of cell phenotypes in HCS: limitations and advantages.

Authors:  Fabio Gasparri
Journal:  Expert Opin Drug Discov       Date:  2009-06       Impact factor: 6.098

4.  β-arrestin2 regulates cannabinoid CB1 receptor signaling and adaptation in a central nervous system region-dependent manner.

Authors:  Peter T Nguyen; Cullen L Schmid; Kirsten M Raehal; Dana E Selley; Laura M Bohn; Laura J Sim-Selley
Journal:  Biol Psychiatry       Date:  2012-01-20       Impact factor: 13.382

Review 5.  Advances in G protein-coupled receptor allostery: from function to structure.

Authors:  Arthur Christopoulos
Journal:  Mol Pharmacol       Date:  2014-07-24       Impact factor: 4.436

6.  Identification of N-arachidonoyl dopamine as a highly biased ligand at cannabinoid CB1 receptors.

Authors:  William J Redmond; Erin E Cawston; Natasha L Grimsey; Jordyn Stuart; Amelia R Edington; Michelle Glass; Mark Connor
Journal:  Br J Pharmacol       Date:  2015-11-17       Impact factor: 8.739

7.  Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions.

Authors:  Somnath Mukhopadhyay; Allyn C Howlett
Journal:  Mol Pharmacol       Date:  2005-03-04       Impact factor: 4.436

Review 8.  Endocannabinoid System in Neurological Disorders.

Authors:  Roberta Ranieri; Chiara Laezza; Maurizio Bifulco; Daniela Marasco; Anna M Malfitano
Journal:  Recent Pat CNS Drug Discov       Date:  2016

9.  Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor.

Authors:  B Bosier; E Hermans; Dm Lambert
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

10.  The CB1 endocannabinoid system modulates adipocyte insulin sensitivity.

Authors:  Roja Motaghedi; Timothy E McGraw
Journal:  Obesity (Silver Spring)       Date:  2008-06-12       Impact factor: 5.002

View more
  1 in total

Review 1.  The endocannabinoid system in cardiovascular function: novel insights and clinical implications.

Authors:  Salvador Sierra; Natasha Luquin; Judith Navarro-Otano
Journal:  Clin Auton Res       Date:  2017-12-08       Impact factor: 4.435

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.